Skip to content

The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease

The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease:A Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05443581
Enrollment
220
Registered
2022-07-05
Start date
2022-07-01
Completion date
2024-05-31
Last updated
2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diet, Healthy, Liver Diseases, Metabolism and Nutrition Disorder, Obesity

Keywords

Metabolism associated fatty liver disease, Obesity, Vegetarian diet, diet intervention

Brief summary

In this study, 18-60 years old patients with metabolic associated fatty liver disease(MAFLD) will be recruited to test the intervention effect of vegetarian diet. This randomized clinical trial randomized individuals to a healthy vegetarian diet or a healthy omnivorous diet for 24 weeks. At the baseline and after the 24week intervention, the clinical manifestations of MAFLD, obesity levels, indices for glucose and lipid metabolism parameters, results of questionnaire and fecal samples will be collected and analyzed.

Detailed description

Dietary control remains an important way for nutritional intervention of metabolic related fatty liver disease. However, studies shows that patients have low compliance to the traditional diet. The topic proposed based on previous studies,recruiting of 220 obesity patients with metabolic associated fatty liver disease aged 18-60. After the informed consent, they will be randomly divided into intervention group and control group, intervention group will be given healthy vegetarian diet intervention and the control group given healthy omnivorous diet. Both diets are in line with the principles of fatty liver treatment. Interventions consisted primarily of face-to -face interview monthly and online interview every 2 weeks, which will be performed by professional dietitians. All participants were asked not to alter their exercise patterns during the study period. The primary outcome was the weight of fat mass after 24 weeks intervention. Secondary outcomes included imaging findings (B-ultrasonic examination and Fibroscan) of MAFLD, liver function, anthropometric measures, plasma lipid and glucose levels. At the meantime, serum oxidative stress indices, results of compliance survey and metabolites of Intestinal flora will be collected and analyzed. Through the above detection of the indicators related to MAFLD and obesity, it is explored whether the vegetarian diet can be an efficient and feasible way to the nutritional therapy of MAFLD.

Interventions

BEHAVIORALdietary intervention

Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Clinically diagnosed as fatty liver, and BMI≥24.0kg/m²; 2. 18-60 years old; 3. Have not received drug treatment if having hyperglycemia, hyperlipidemia and high uric acid ; 4. No antibiotics in the last 1 month; 5. The guardian's informed consent;

Exclusion criteria

1. Have received drug treatment of fatty liver disease within three months; 2. Patients with with liver cirrhosis, viral hepatitis and other liver diseases; 3. Patients with serious heart, lung, kidney diseases and patients with cancer; 4. Pregnant and nursing women; 5. Other conditions that may affect the results of the study

Design outcomes

Primary

MeasureTime frameDescription
The primary outcome was the weight of fat mass after 24 weeks intervention.24 weeksWeight loss, especially the reduction of body fat mass, is the most important treatment for the prevention and treatment of MAFLD and its complicationsIn our study, we will measure weight of fat mass using a body composition analyzer (Biospace Inbody 720, Korea) at the baseline and after 24-week intervention. The difference in the weight of fat mass after intervention between the two groups is the primary outcome.

Secondary

MeasureTime frameDescription
The changes of serum alanine aminotransferase (ALT) at week 24 intervention from the baseline24 weeksHepatic steatosis is often accompanied by changes in hepatic enzymes.
Results of B-ultrasonic examination and Fibroscan examination24 weeksImaging examination results are an important basis for the clinical diagnosis of NAFLD, which can show the degree of hepatic steatosis and hepatic fibrosis. Imaging findings of MAFLD will be measured and compared at the baseline and end of our study.
The changes of serum aspartate aminotransferase (AST) at week 24 intervention from the baseline24 weeksHepatic steatosis is often accompanied by changes in hepatic enzymes.
24-week weight change24 weeksThe 24-week intervention is expected to bring weight loss. We will compare the weight loss between the two groups

Other

MeasureTime frameDescription
The difference of metabolites of Intestinal flora between two groups after 24-week intervention.24 weeksThe fecal samples before and after the intervention to examine the effect of vegetarian diets on gut microbiota metabolites.
The difference of serum superoxide dismutase (SOD) level between two groups after 24-week intervention24 weeksCause vegetarian diet may contain more phytochemicals and less saturated fat and cholesterol due to the plant-based nature of the diet, resulting in better metabolic status and milder metabolic burden,we have presumed that the serum SOD level be different between two groups at the end of study.
The Results of compliance survey will be collected every month.24 weeksWe have designed a compliance scale to evaluate the compliance , which may be important to advise the nutritionists and doctors about the prevention and treatment of MAFLD.

Countries

China

Contacts

Primary ContactXiuhua Shen, Professor
srachel@126.com+86-139-1691-0428
Backup ContactKaijie Xu, Master
kaijie111xu@126.com+86-150-2668-6958

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026